Real-time enrollment status for this metastatic hormone-sensitive prostate cancer (mhspc) clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 10:22 PM UTC
| NCT Number | NCT07190300 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
| Phase | PHASE1 |
| Target Enrollment | 181 participants |
| Active Locations | 8 sites in the US |
| Sponsor | Novartis Pharmaceuticals |
| Last Updated on CT.gov | June 23, 2026 (Jun 23, 2026) |
As of August 27, 2026: Clinical trial NCT07190300 is currently recruiting participants. This phase1 study for metastatic hormone-sensitive prostate cancer (mhspc) is actively seeking new participants at 8 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07190300 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07190300 was last updated Jun 23, 2026 (June 23, 2026). HelloStudys verifies this status automatically.